194 related articles for article (PubMed ID: 32729417)
1. The Potential Therapeutic Role of the HMGB1-TLR Pathway in Epilepsy.
Wang S; Guan Y; Li T
Curr Drug Targets; 2021; 22(2):171-182. PubMed ID: 32729417
[TBL] [Abstract][Full Text] [Related]
2. Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy.
Walker LE; Frigerio F; Ravizza T; Ricci E; Tse K; Jenkins RE; Sills GJ; Jorgensen A; Porcu L; Thippeswamy T; Alapirtti T; Peltola J; Brodie MJ; Park BK; Marson AG; Antoine DJ; Vezzani A; Pirmohamed M
J Clin Invest; 2017 Jun; 127(6):2118-2132. PubMed ID: 28504645
[TBL] [Abstract][Full Text] [Related]
3. High mobility group box 1 (HMGB1) as a novel frontier in epileptogenesis: from pathogenesis to therapeutic approaches.
Paudel YN; Semple BD; Jones NC; Othman I; Shaikh MF
J Neurochem; 2019 Dec; 151(5):542-557. PubMed ID: 30644560
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1.
Maroso M; Balosso S; Ravizza T; Liu J; Bianchi ME; Vezzani A
J Intern Med; 2011 Oct; 270(4):319-26. PubMed ID: 21793950
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of HMGB1, toll-like receptor and RAGE in human Rasmussen's encephalitis.
Luan G; Gao Q; Zhai F; Chen Y; Li T
Epilepsy Res; 2016 Jul; 123():36-49. PubMed ID: 27108105
[TBL] [Abstract][Full Text] [Related]
6. HMGB1: A Common Biomarker and Potential Target for TBI, Neuroinflammation, Epilepsy, and Cognitive Dysfunction.
Paudel YN; Shaikh MF; Chakraborti A; Kumari Y; Aledo-Serrano Á; Aleksovska K; Alvim MKM; Othman I
Front Neurosci; 2018; 12():628. PubMed ID: 30271319
[TBL] [Abstract][Full Text] [Related]
7. High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.
Ravizza T; Terrone G; Salamone A; Frigerio F; Balosso S; Antoine DJ; Vezzani A
Brain Behav Immun; 2018 Aug; 72():14-21. PubMed ID: 29031614
[TBL] [Abstract][Full Text] [Related]
8. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein.
Park JS; Svetkauskaite D; He Q; Kim JY; Strassheim D; Ishizaka A; Abraham E
J Biol Chem; 2004 Feb; 279(9):7370-7. PubMed ID: 14660645
[TBL] [Abstract][Full Text] [Related]
9. Serum concentration of high-mobility group box 1, Toll-like receptor 4 as biomarker in epileptic patients.
Yue Z; Tang J; Peng S; Cai X; Rong X; Yang L
Epilepsy Res; 2023 May; 192():107138. PubMed ID: 37075527
[TBL] [Abstract][Full Text] [Related]
10. Expatiating the molecular approaches of HMGB1 in diabetes mellitus: Highlighting signalling pathways via RAGE and TLRs.
Behl T; Sharma E; Sehgal A; Kaur I; Kumar A; Arora R; Pal G; Kakkar M; Kumar R; Bungau S
Mol Biol Rep; 2021 Feb; 48(2):1869-1881. PubMed ID: 33479829
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of an anti-high mobility group box-1 monoclonal antibody in epilepsy.
Zhao J; Wang Y; Xu C; Liu K; Wang Y; Chen L; Wu X; Gao F; Guo Y; Zhu J; Wang S; Nishibori M; Chen Z
Brain Behav Immun; 2017 Aug; 64():308-319. PubMed ID: 28167116
[TBL] [Abstract][Full Text] [Related]
12. Circulating high mobility group box-1 and toll-like receptor 4 expressions increase the risk and severity of epilepsy.
Kan M; Song L; Zhang X; Zhang J; Fang P
Braz J Med Biol Res; 2019; 52(7):e7374. PubMed ID: 31241711
[TBL] [Abstract][Full Text] [Related]
13. A Systematic Review of the Predictive and Diagnostic Uses of Neuroinflammation Biomarkers for Epileptogenesis.
Aguilar-Castillo MJ; Cabezudo-García P; García-Martín G; Lopez-Moreno Y; Estivill-Torrús G; Ciano-Petersen NL; Oliver-Martos B; Narváez-Pelaez M; Serrano-Castro PJ
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928193
[TBL] [Abstract][Full Text] [Related]
14. High mobility group box-1 induces pro-inflammatory signaling in human nucleus pulposus cells via toll-like receptor 4-dependent pathway.
Shah BS; Burt KG; Jacobsen T; Fernandes TD; Alipui DO; Weber KT; Levine M; Chavan SS; Yang H; Tracey KJ; Chahine NO
J Orthop Res; 2019 Jan; 37(1):220-231. PubMed ID: 30273982
[TBL] [Abstract][Full Text] [Related]
15. Role of Innate Immune Receptor TLR4 and its endogenous ligands in epileptogenesis.
Paudel YN; Angelopoulou E; Akyuz E; Piperi C; Othman I; Shaikh MF
Pharmacol Res; 2020 Oct; 160():105172. PubMed ID: 32871246
[TBL] [Abstract][Full Text] [Related]
16. Insulin infusion suppresses while glucose infusion induces Toll-like receptors and high-mobility group-B1 protein expression in mononuclear cells of type 1 diabetes patients.
Dandona P; Ghanim H; Green K; Sia CL; Abuaysheh S; Kuhadiya N; Batra M; Dhindsa S; Chaudhuri A
Am J Physiol Endocrinol Metab; 2013 Apr; 304(8):E810-8. PubMed ID: 23403945
[TBL] [Abstract][Full Text] [Related]
17. The Role of High Mobility Group Box-1 in Epileptogenesis.
Fu L; Nishibori M
Acta Med Okayama; 2019 Oct; 73(5):383-386. PubMed ID: 31649363
[TBL] [Abstract][Full Text] [Related]
18. The Emerging Role of HMGB1 in Neuropathic Pain: A Potential Therapeutic Target for Neuroinflammation.
Wan W; Cao L; Khanabdali R; Kalionis B; Tai X; Xia S
J Immunol Res; 2016; 2016():6430423. PubMed ID: 27294160
[TBL] [Abstract][Full Text] [Related]
19. High-mobility group box-1 in sterile inflammation.
Tsung A; Tohme S; Billiar TR
J Intern Med; 2014 Nov; 276(5):425-43. PubMed ID: 24935761
[TBL] [Abstract][Full Text] [Related]
20. Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.
Angelopoulou E; Piperi C; Adamopoulos C; Papavassiliou AG
J Mol Med (Berl); 2016 Aug; 94(8):867-74. PubMed ID: 27262996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
